Opthea’s Wet AMD Program to be Featured at FLORetina 2024
November 26, 2024 07:00 ET
|
Opthea Limited
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea to Participate in Citi 2024 Global Healthcare Conference
November 25, 2024 07:00 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Appoints Kathy Connell to Board of Directors
November 15, 2024 07:00 ET
|
Opthea Limited
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON,...
Opthea’s Wet AMD Program Featured at Ophthalmology Events
November 12, 2024 07:00 ET
|
Opthea Limited
17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024 Ophthalmology Innovation Summit XIV, November 23, 2024 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE...
Opthea to Participate in November Investor Conferences
November 04, 2024 07:00 ET
|
Opthea Limited
Virtual Bell Potter Healthcare Conference, November 18, 2024 Jefferies London Healthcare Conference, November 19, 2024 MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) --...
Opthea Files Notice of Annual General Meeting
October 16, 2024 07:00 ET
|
Opthea Limited
Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s...
Opthea Wet AMD Program to be Presented at Innovate Retina
October 10, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025
October 08, 2024 07:00 ET
|
Opthea Limited
Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE)...
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
September 30, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Joins the S&P/ASX 300 Index
September 23, 2024 07:00 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...